SCHEMBL16611364

SCHEMBL16611364

COC(=O)C1CCN(c2ccc(N)cc2)CC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.66
GFER P55789 2/20 0.51
CASP6 P55212 1/20 0.51
KMT2A Q03164 2/20 0.51
MEN1 O00255 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
LMNA P02545 1/20 0.51
LGMN Q99538 2/20 0.50
PDE3B Q13370 1/20 0.49
PDE3A Q14432 1/20 0.49
PDK2 Q15119 1/20 0.49
KDM4E B2RXH2 2/20 0.49
HSD17B10 Q99714 1/20 0.47
ALDH1A1 P00352 3/20 0.47
GAA P10253 1/20 0.46
ADRA2C P18825 1/20 0.46
PTK2B Q14289 1/20 0.46
ESR2 Q92731 1/20 0.46
TP53 P04637 1/20 0.45
PKM P14618 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14712096 0.91 MAPT (0.56) MAPTGFERCASP6KMT2AMEN1
SCHEMBL14711368 0.91 MAPT (0.56) MAPTGFERCASP6KMT2AMEN1
SCHEMBL12082135 0.86 MAPT (0.68) MAPTKMT2AMEN1SMN1; SMN2LGMN
SCHEMBL25262380 0.84 MAPT (0.66) MAPTKMT2AMEN1SMN1; SMN2LMNA
SCHEMBL16610843 0.84 MAPT (0.66) MAPTKMT2AMEN1SMN1; SMN2LMNA
SCHEMBL13896503 0.84 MAPT (0.66) MAPTKMT2AMEN1SMN1; SMN2LMNA
SCHEMBL14862078 0.84 MAPT (0.66) MAPTKMT2AMEN1SMN1; SMN2LMNA
SCHEMBL1221442 0.84 MAPT (0.65) MAPTKMT2AMEN1SMN1; SMN2PDE3B
SCHEMBL3713571 0.84 NAMPT (0.48) MAPTGFERCASP6KMT2AMEN1
SCHEMBL27543 0.84 LGMN (0.70) MAPTKMT2AMEN1LGMNPDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026098560-A2 BENZENE-CONTAINING POLYCYCLIC DERIVATIVE MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF 上海翰森生物医药科技有限公司 2026-05-15 WO disclosed
US-20160251352-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2016-09-01 US disclosed
US-9371320-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-21 US disclosed
US-20150141406-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-05-21 US disclosed
EP-2857400-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2015-04-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160251352-A1 HETEROCYCLIC COMPOUND JAK2, JAK1, STAT3 MAPT 1208/4885GFER 4151/4885CASP6 2074/4885
US-20150141406-A1 HETEROCYCLIC COMPOUND JAK2, JAK1, STAT3 MAPT 1208/4885GFER 4151/4885CASP6 2074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.